Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from I-MAB ( (IMAB) ) is now available.
On October 28, 2025, NovaBridge Biosciences’ subsidiary, Visara, entered into an agreement with Everest Medicines to assign its exclusive license for VIS-101, a novel bifunctional biologic, for development and commercialization in Greater China and other Asian markets. This strategic move aims to leverage Everest’s clinical and commercialization expertise to accelerate VIS-101’s development for treating wet AMD, DME, and RVO. Additionally, NovaBridge appointed Ian Woo to its Board of Directors, bringing significant biopharma finance and management expertise to the company, which is expected to enhance its strategic operations and global development efforts.
The most recent analyst rating on (IMAB) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on I-MAB stock, see the IMAB Stock Forecast page.
Spark’s Take on IMAB Stock
According to Spark, TipRanks’ AI Analyst, IMAB is a Neutral.
The overall stock score of 45 reflects I-MAB’s substantial financial challenges, particularly in terms of profitability and cash flow generation, which heavily impact its financial performance. Despite a modest technical uptrend, valuation metrics point to significant risks, with ongoing losses and a negative P/E ratio limiting its appeal. The absence of recent earnings call data or notable corporate events further solidifies the overall cautious outlook.
To see Spark’s full report on IMAB stock, click here.
More about I-MAB
NovaBridge Biosciences is a global biotechnology platform company focused on accelerating access to innovative medicines. The company combines business development expertise with translational clinical development to advance breakthrough assets. Its pipeline includes givastomig, a bispecific antibody for cancer treatment, and VIS-101, a biologic targeting VEGF-A and ANG2 for ophthalmic conditions.
Average Trading Volume: 2,740,021
Technical Sentiment Signal: Buy
Current Market Cap: $366.7M
For an in-depth examination of IMAB stock, go to TipRanks’ Overview page.